Fennec Pharmaceuticals Shares Down After 4Q Results

Dow Jones

2025/03/11

By Josh Beckerman

Fennec Pharmaceuticals shares were down after the company reported fourth-quarter results.

The stock was recently down 10% to $6.20 and is down about 2% this year.

Revenue declined to $7.93 million from $9.74 million. Analysts surveyed by FactSet, on average, expected $7.9 million. Loss was 6 cents a share, compared with analysts' estimates for a loss of 13 cents a share.

In September 2022, the Food and Drug Administration approved Fennec's Pedmark, a sodium thiosulfate formulation, to reduce the risk of ototoxicity associated with cisplatin in certain pediatric patients with tumors.

Fennec said Monday that it is seeing encouraging momentum in early 2025, particularly with adoption by academic institutions and new patient segments. A Pedmark clinical trial in Japan fully enrolled in the fourth quarter and results are expected in the second half of 2025.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

March 10, 2025 15:37 ET (19:37 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2518202628"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2518202628\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2518202628?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-11 03:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518202628","market":"sg","top_or_hot":-1,"title":"Fennec Pharmaceuticals Shares Down After 4Q Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Fennec Pharmaceuticals shares were down after the company reported fourth-quarter results. \n</p>\n<p>\n  The stock was recently down 10% to $6.20 and is down about 2% this year. \n</p>\n<p>\n  Revenue declined to $7.93 million from $9.74 million. Analysts surveyed by FactSet, on average, expected $7.9 million. Loss was 6 cents a share, compared with analysts' estimates for a loss of 13 cents a share. \n</p>\n<p>\n  In September 2022, the Food and Drug Administration approved Fennec's Pedmark, a sodium thiosulfate formulation, to reduce the risk of ototoxicity associated with cisplatin in certain pediatric patients with tumors. \n</p>\n<p>\n  Fennec said Monday that it is seeing encouraging momentum in early 2025, particularly with adoption by academic institutions and new patient segments. A Pedmark clinical trial in Japan fully enrolled in the fourth quarter and results are expected in the second half of 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 10, 2025 15:37 ET (19:37 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fennec Pharmaceuticals Shares Down After 4Q Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFennec Pharmaceuticals Shares Down After 4Q Results\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-03-11 03:37</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Fennec Pharmaceuticals shares were down after the company reported fourth-quarter results. \n</p>\n<p>\n  The stock was recently down 10% to $6.20 and is down about 2% this year. \n</p>\n<p>\n  Revenue declined to $7.93 million from $9.74 million. Analysts surveyed by FactSet, on average, expected $7.9 million. Loss was 6 cents a share, compared with analysts' estimates for a loss of 13 cents a share. \n</p>\n<p>\n  In September 2022, the Food and Drug Administration approved Fennec's Pedmark, a sodium thiosulfate formulation, to reduce the risk of ototoxicity associated with cisplatin in certain pediatric patients with tumors. \n</p>\n<p>\n  Fennec said Monday that it is seeing encouraging momentum in early 2025, particularly with adoption by academic institutions and new patient segments. A Pedmark clinical trial in Japan fully enrolled in the fourth quarter and results are expected in the second half of 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 10, 2025 15:37 ET (19:37 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FENC","symbol_name":"Fennec Pharmaceuticals Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2518202628","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518202628","pubTimestamp":1741635420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Fennec Pharmaceuticals shares were down after the company reported fourth-quarter results.The stock was recently down 10% to $6.20 and is down about 2% this year.Revenue declined to $7.93 million from $9.74 million. Analysts surveyed by FactSet, on average, expected $7.9 million. Loss was 6 cents a share, compared with analysts' estimates for a loss of 13 cents a share.In September 2022, the Food and Drug Administration approved Fennec's Pedmark, a sodium thiosulfate formulation, to reduce the risk of ototoxicity associated with cisplatin in certain pediatric patients with tumors.Fennec said Monday that it is seeing encouraging momentum in early 2025, particularly with adoption by academic institutions and new patient segments. A Pedmark clinical trial in Japan fully enrolled in the fourth quarter and results are expected in the second half of 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FENC":"Fennec Pharmaceuticals Inc.","BK4139":"生物科技"},"translate_title":"Fennec Pharmaceuticals第四季度业绩公布后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FENC":0.9},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Fennec Pharmaceuticals shares were down after the company reported fourth-quarter results. \n\n\n  The stock was recently down 10% to $6.20 and is down about 2% this year. \n\n\n  Revenue declined to $7.93 million from $9.74 million. Analysts surveyed by FactSet, on average, expected $7.9 million. Loss was 6 cents a share, compared with analysts' estimates for a loss of 13 cents a share. \n\n\n  In September 2022, the Food and Drug Administration approved Fennec's Pedmark, a sodium thiosulfate formulation, to reduce the risk of ototoxicity associated with cisplatin in certain pediatric patients with tumors. \n\n\n  Fennec said Monday that it is seeing encouraging momentum in early 2025, particularly with adoption by academic institutions and new patient segments. A Pedmark clinical trial in Japan fully enrolled in the fourth quarter and results are expected in the second half of 2025. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2025 15:37 ET (19:37 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}